Patent application number | Description | Published |
20100048471 | ANGIOGENESIS INHIBITOR COMPRISING METEORIN AS AN ACTIVE INGREDIENT - The present invention relates to an angiogenesis inhibitor comprising meteorin as an active ingredient that is highly expressed in astrocytes of the brain and retina in the late embryonic stage and after the birth of a mouse. It is in particular highly detected in astrocyte endfeet surrounding blood vessels and promotes the expression of thrombospondin-1/-2 (TSP-1/-2) via autocrine pathway and thus inhibits angiogenesis. The meteorin of the present invention can be effectively used for pharmaceutical compositions and health foods that prevent vascular diseases by inhibiting angiogenesis. | 02-25-2010 |
20100068315 | Composition Comprising an Extract of Gramineae Plant for the Prevention and Treatment of Ischemic Diseases and Degenerative Brain Diseases and the Use Thereof - The present invention relates to a composition comprising extracts of Gramineae plant that improves cell viability under hypoxic conditions by inhibiting apoptosis. Thus, the extract of | 03-18-2010 |
20110123538 | COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN 1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE - The present invention relates to a composition comprising a Ninjurin 1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin 1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin 1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin 1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease. | 05-26-2011 |
20110162092 | COMPOSITION COMPRISED OF AKAP12 AND USES OF AKAP12 MUTANT ZEBRAFISH AS AN ANIMAL MODEL - The present invention relates to a composition comprised of AKAP12 (A-Kinase anchoring protein 12) and to uses of AKAP12 mutant zebrafish as an animal model. More particularly, the following characteristics are noted in the present AKAP12 mRNA knockdown zebrafish: crooked or shortened tail, inability to move normally, non-uniform micro-vasculature in the brain, and change in heart shape with non-uniform and weak heartbeats. It also has various circulatory and genetic defects, such as hemorrhage from the ventricles of the heart, brain, and retina. All of these defects can be cured with AKAP12 injection. Therefore, AKAP12 can be used as an active component for a composition to prevent and heal circulatory and genetic defects that are caused by AKAP12 deficiency, and as a hemorrhage inhibitor. Further, the AKAP12 deficient mutant zebrafish can be useful as an animal model for verification of effectiveness of treatment for genetic defects in the circulatory system. | 06-30-2011 |
20110171661 | METHOD FOR DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA - Provided are a method of diagnosing the recurrence or possibility of recurrence of hepa | 07-14-2011 |
20110250193 | COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE - The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7 | 10-13-2011 |
20130330361 | Composition Comprising Expression or Activity Regulators of AKAP12 for Treating Central Nerve System Diseases - The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury. | 12-12-2013 |
20140037640 | COMPOSITION COMPRISING EXPRESSION OR ACTIVITY INHIBITORS OF NINJURIN1 FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE - The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease. | 02-06-2014 |